Lilly obtains FDA approval for Mounjaro to treat type 2 diabetes in adults
Mounjaro will be offered in six doses, 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg, together with Lilly’s auto-injector…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
16 May 22
Mounjaro will be offered in six doses, 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg, together with Lilly’s auto-injector…
16 May 22
Radicava ORS comes in a small, 5mL dose, with portable bottle, oral dosing syringe, and eliminates the need…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
13 May 22
BBP-398 is an inhibitor of SHP2 and was founded through a partnership with the Therapeutics Discovery division of…
13 May 22
The transaction also includes a strategic partnership to jointly develop and market Cullinan Oncology’s lead programme, CLN-081/TAS6417, an…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
12 May 22
The Phase 3 study evaluated the tiragolumab plus Tecentriq in 534 patients with first-line PD-L1-high metastatic non-small cell…
11 May 22
The proposed deal includes the acquisition of Biohaven’s calcitonin gene-related peptide (CGRP) programme, including rimegepant, zavegepant and a…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
11 May 22
CEPI will provide up to $19.3m funding to an international multidisciplinary consortium comprising India’s Bharat Biotech International (BBIL),…
10 May 22
Lecanemab is indicated for mild cognitive impairment (MCI) due to AD and mild AD (collectively early AD), in…
10 May 22
Sunosi is indicated to improve wakefulness in adult patients suffering from excessive daytime sleepiness (EDS) due to narcolepsy…
09 May 22
The company intends to use the proceeds from the funding to ramp up the ongoing clinical trials of…